Chemotherapy for melanoma: The resultant of conflicting vectors

Journal of Clinical Oncology

Volumn 22, Issue 11, 2004, Pages 2043-2045

  Mitchell, Malcolm S ^a  

^a Van Elslander Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; DACARBAZINE;

ANIMAL; DRUG EFFECT; DRUG RESISTANCE; HUMAN; MELANOMA; METABOLISM; MOUSE; NOTE; SKIN TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; HUMANS; MELANOMA; MICE; SKIN NEOPLASMS;

EID: 2942650927     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2004.03.976     Document Type: Editorial

References (17)

1. Eton O, Legha SS, Bedikian AY, et al: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol 20:2045-2052, 2002
2. Lens MB, Eisen TG: Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother 4:2205-2211, 2003
3. Atkins MB, Kunkel L, Sznol M, et al: High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am 6:S11-14, 2000 (suppl 1)
4. Lev DC, Onn A, Melinkova VO, et al: Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol 22:2092-2100, 2004
5. Lev DC, Ruiz M, Mills L, et al: Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: A possible escape mechanism from chemotherapy. Mol Cancer Ther 2:753-763, 2003
6. Hwu WJ, Krown SE, Menell JH, et al: Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 21:3351-3356, 2003
7. Ben-Efraim S, Bizzini B, Relyveld EH: Use of xenogenized (modified) tumor cells for treatment in experimental tumor and in human neoplasia. Biomed Pharmacother 54:268-273, 2000
8. Kobayashi H: Viral xenogenization of intact tumor cells. Adv Cancer Res 30:279-299, 1979
9. Berd D: Autologous hapten-modified vaccine as a treatment for human cancers. Vaccine 19:2565-2570, 2001
10. Contessa AR, Bonmassar A, Giampietri A, et al: In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(33'-dimethyl-1-triazeno)imidazole-4-carboxamide. Cancer Res 41:2476-2482, 1981
11. Mitchell MS: Combining chemotherapy with biological response modifiers in the treatment of cancer. J Natl Cancer Inst 80:1445-1450, 1988
12. Spreafico F: Heterogeneity of the interaction of anticancer agents with the immune system and its possible relevance in chemoimmunotherapy. Oncology 37:9-18, 1980 (suppl 1)
13. Kempf RA, Cebul RD, Mitchell MS: Antitumor effects of doxorubicin against a virally-induced rat osteosarcoma with minimal immunosuppression. J Immunopharmacol 2:509-525, 1981
14. Bruckner HW, Mokyr MB, Mitchell MS: Effect of imidazole-4- carboxamide 5-(33-dimethyl-1-triazeno) on immunity in patients with malignant melanoma. Cancer Res 34:181-183, 1974
15. Mitchell MS, Mokyr MB, Davis JM: Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma. J Clin Invest 57:517-526, 1977
16. Murahata RI, Mitchell MS: Modulation of the immune response by BCG: A review. Yale J Biol Med 49:283-291, 1976
17. Berd D, Mitchell MS: Immunologic enhancement of leukemia L-1210 by Corynebacterium parvum in allogeneic mice. Cancer Res 36:4119-4124, 1976